A phase 1 study of KT-413, a dual degrader of IRAK4 and IMiD substrates, in patients with DLBCL

In March 2020, LLS made an equity investment in Kymera Therapeutics to "Support Key Studies with IRAK4 Protein Degraders for Future Development in Hematological Patients."

Kymera Therapeutics is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Whereas most targeted therapies inhibit or inactivate the proteins or genes that drive the cancer, targeted protein degradation harnesses the body’s natural system of ridding itself of unwanted, “old” or “broken” components of cells.

KT-413 is a dual protein degrader of IRAK4 and IMiD substrates. KT-413 is in a Phase 1 clinical trial currently enrolling DLBCL patients (NCT05233033).